Evidence map›Paper›PMID 34595431›Full record

ArticleClinical hematology international2019

Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation.

Zachariah DeFilipp, Nalu Navarro-Alvarez, Shuli Li, Alec R Andrews, Ariel Johnson, Yi-Bin Chen, Vincent T Ho, Jerome Ritz, Thomas R Spitzer, Christene A Huang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical hematology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Zachariah DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA.
Nalu Navarro-AlvarezCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Shuli LiDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
Alec R AndrewsCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Ariel JohnsonDepartment of Surgery, Division of Plastic & Reconstructive Surgery, Division of Transplant Surgery, University of Colorado School of Medicine, Aurora, CO.
Yi-Bin ChenBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA.
Vincent T HoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jerome RitzDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Thomas R SpitzerBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA.
Christene A HuangCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Massachusetts General Hospital · USDana-Farber Cancer Institute · USUniversity of Colorado Denver · US

Funding

Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5M
Manipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7M
Reconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5M
NCI NIH HHS P01 CA142106NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560
6 · The paper itself

Abstract

Galectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD). Plasma galectin-3 concentrations were measured at 1 year post-HCT and correlated with clinical data collected from individual medical records. The median serum galectin-3 level at that time point was 14.9 ng/mL (range, 5.5-61.6), which was significantly higher than that among healthy controls (14.9 versus 6.2,

Indexed as

Allogeneic hematopoietic cell transplantationChronic graft-versus-host diseaseGalectin-3

Identifiers

PMID34595431
PMCPMC8432371
OpenAlexW2972963387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.